Waystar explores potential sale as healthcare software valuation gap draws buyer interest

Waystar Holding Corp. (NASDAQ: WAY) is exploring strategic options that include a potential sale, less than three years after the healthcare payments software company returned to public markets. Reuters reported on September 15 that Waystar Holding Corp. has engaged Evercore and Barclays to advise on an early-stage process, although the plans could change and no transaction may ultimately occur. The report pushed Waystar shares sharply higher, lifting the company’s equity value to roughly $5.1 billion and enterprise value to about $6.4 billion at the September 15 close. A potential buyer would be acquiring a healthcare software platform that generated 18% second-quarter revenue growth and a 43% adjusted EBITDA margin while connecting hospitals, physicians, payers and patients across the healthcare payment cycle. The central tension is whether a strategic or private equity buyer would pay enough for Waystar’s recurring software economics and artificial intelligence potential to justify taking the company private after its public valuation fell materially from its 2025 peak.

Why could Waystar Holding Corp. attract takeover interest only two years after its Nasdaq listing?

Waystar Holding Corp. returned to public markets in 2024 after years of private equity ownership, but the company’s share-price trajectory has created a potential opening for another take-private transaction. The stock reached approximately $45 during 2025 before falling sharply as investors reassessed software valuations and debated how artificial intelligence could affect established enterprise software models. Even after the September 15 rally, Waystar remained substantially below its earlier high.

The operating business has performed more strongly than that share-price decline might suggest. Second-quarter 2026 revenue increased 18% year on year to $319.7 million, adjusted EBITDA rose to $136.7 million and the adjusted EBITDA margin reached 43%. Subscription revenue increased 34%, while the number of clients generating more than $100,000 of trailing 12-month revenue rose 15% to 1,453.

That combination can attract financial buyers because a lower public valuation does not necessarily imply deteriorating underlying economics. A company with recurring software revenue, high margins, customer retention and predictable healthcare workflows can support substantial leverage if cash generation remains durable. The takeover question is therefore less about rescuing Waystar and more about whether a private owner sees more long-term value than the public market currently recognises.

What exactly does Waystar provide to hospitals and physicians across the healthcare payment cycle?

Waystar provides software used by healthcare organisations to manage administrative and financial processes surrounding patient care. Its platform connects providers, payers and patients across activities including claims processing, payment accuracy, prior authorisation, patient financial engagement and revenue-cycle administration. These processes sit behind clinical care but materially influence how quickly hospitals and medical practices convert services into cash.

The strategic importance comes from the complexity of the United States healthcare payment system. Providers must submit claims using detailed coding and eligibility rules, respond to payer requirements, manage denials and collect patient balances. Software that automates those workflows can reduce labour requirements, improve claim accuracy and accelerate reimbursement.

Waystar also benefits from integration into customers’ daily operations. Replacing revenue-cycle software can require technology changes, workflow redesign and employee retraining, creating switching costs that support recurring revenue and customer retention. Waystar reported net revenue retention of 108% in the second quarter, indicating that existing customers collectively increased their spending even after accounting for customer losses.

Why could artificial intelligence strengthen Waystar’s valuation rather than simply threaten its software model?

Artificial intelligence has contributed to investor uncertainty across the software sector because customers may eventually automate tasks previously handled by specialised applications. Waystar faces that debate directly because many healthcare revenue-cycle processes involve repetitive administrative work that appears suitable for automation. A potential acquirer must determine whether artificial intelligence commoditises parts of Waystar’s platform or makes its existing data and workflow position more valuable.

Waystar has been developing artificial intelligence capabilities through its AltitudeAI platform, using automation to improve claims workflows, payment accuracy and administrative productivity. The company has access to large volumes of healthcare transaction data, which can become more useful when models are trained to identify patterns associated with denials, billing errors and reimbursement delays. The strategic advantage is therefore not simply owning an artificial intelligence interface, but embedding automated decision support inside established healthcare-payment workflows.

The strongest scenario is one in which artificial intelligence improves Waystar’s economics by reducing manual processing while increasing the value customers receive from the platform. The weaker scenario is that competing software providers or healthcare organisations develop comparable capabilities and reduce willingness to pay premium prices for standalone solutions. Any buyer considering a multibillion-dollar acquisition must form a view on that competitive question before assigning a long-term valuation.

How do Waystar’s 43% adjusted EBITDA margin and recurring revenue affect potential deal economics?

Waystar’s margin profile is central to its potential appeal. Second-quarter adjusted EBITDA of $136.7 million represented approximately 43% of revenue, giving the company considerably stronger operating margins than many labour-intensive healthcare services businesses. That supports Waystar’s positioning as a software company rather than a traditional outsourced revenue-cycle operator.

The company also generated $59.4 million of operating cash flow and $63.9 million of unlevered free cash flow during the quarter. Subscription revenue of $176.3 million grew substantially faster than volume-based revenue, improving the contribution from recurring contractual economics. These characteristics can support higher transaction multiples because buyers place greater value on earnings streams that require relatively limited incremental capital to grow.

At the September 15 share price of $26.67, Waystar had a market capitalisation of approximately $5.1 billion and an enterprise value near $6.4 billion. Those figures provide a market reference rather than a takeover valuation because any buyer would likely need to offer a premium sufficient to win board and shareholder support. The required premium becomes particularly important when a company’s shares have recently rebounded on takeover speculation.

How would Waystar’s existing debt affect a potential private equity acquisition?

Waystar reported approximately $1.47 billion of outstanding debt at June 30, including its first-lien term loan and receivables facility. The company held only $12.6 million of cash and cash equivalents on the balance sheet, although it also carried approximately $179 million of investment securities. The capital structure therefore already contains meaningful leverage before any potential acquisition financing is considered.

A private equity buyer could refinance existing obligations and add acquisition debt, but the amount would depend on interest rates, lender appetite and confidence in Waystar’s recurring cash generation. High adjusted EBITDA margins support debt capacity, while healthcare software revenue can offer greater stability than more cyclical technology markets. However, excessive leverage could constrain product investment or acquisitions if revenue growth slows.

A strategic buyer would face a different calculation. A larger healthcare technology company might fund more of the consideration with existing cash, corporate debt or stock and could potentially justify a higher valuation through cost savings or cross-selling opportunities. No bidder has been identified publicly, so any discussion of likely acquirers remains speculative at this stage.

Why do Waystar’s private equity shareholders matter if a sale process develops?

Waystar was created through the 2017 combination of ZirMed and Navicure and subsequently developed under private equity ownership before its 2024 listing. EQT remained the largest shareholder with approximately 13% of Waystar according to market data cited in the September 15 Reuters report, while Canada Pension Plan Investment Board held around 10%. BlackRock Institutional Trust Company was another significant shareholder.

The presence of large institutional holders can influence transaction dynamics because a buyer seeking full control ultimately needs shareholder support at an acceptable valuation. Earlier private equity sponsors also understand Waystar’s operating model and historical valuation closely, which may shape expectations around what constitutes an adequate exit price. A transaction that simply restores the stock to previous highs may not automatically satisfy every shareholder if operating performance continues improving.

The ownership structure could nevertheless make a formal sale process more manageable because several significant shareholders can evaluate strategic alternatives through a concentrated institutional lens. Their interests are not necessarily identical, but each will compare any acquisition premium with the value available from remaining public and participating in future growth.

What does Waystar’s September share-price rally reveal about expectations for a possible sale?

Waystar shares closed at $26.67 on September 15, rising 7.1% during the session after the potential-sale report circulated. The stock had already risen 6.1% on September 14, bringing the increase from the September 9 close of $23.86 to approximately 11.8% across four trading sessions. Compared with the August 17 close of $24.68, the shares were roughly 8.1% higher over about one month.

The stock nevertheless remained far below its 52-week high, with the latest annual trading range extending from approximately $17.26 to $40.35. That gap helps explain why a potential sale may attract attention even after the recent rebound. A buyer could perceive an opportunity to offer a meaningful premium to current trading levels while still acquiring the business below the valuation implied by Waystar’s earlier market peak.

The share-price increase should not be interpreted as confirmation that a transaction will occur. Reuters reported that the process remains at an early stage and could change, while Waystar declined to comment publicly on the report. Until the company announces a formal strategic review, receives an offer or enters an agreement, the correct description remains that Waystar is reported to be exploring options that include a possible sale.

What would determine whether selling Waystar creates more value than remaining publicly listed?

The first test is valuation. Waystar raised its 2026 revenue and adjusted EBITDA guidance after the second quarter, meaning any prospective buyer must value a business whose operating performance is still improving. A modest acquisition premium could fail to compensate shareholders for giving up future growth if subscription revenue and artificial intelligence products continue scaling.

The second test is the durability of Waystar’s competitive position. Healthcare payment software remains attractive because administrative complexity is persistent, but artificial intelligence could change both customer expectations and competitive economics. A buyer willing to take a long-duration view may accept near-term technology spending that public investors currently value cautiously.

The third test is execution if no transaction occurs. Waystar does not require a sale to continue growing. The company can strengthen the standalone thesis by sustaining double-digit revenue growth, expanding free cash flow and demonstrating that AltitudeAI increases customer value rather than threatening existing revenue streams.

The strategic position has therefore improved without producing a definitive transaction. Takeover interest can highlight the value embedded in a company, but the next measurable proof point is whether Waystar actually launches a formal process or receives an actionable proposal. The thesis strengthens if strong operating results encourage bidders to pay a substantial premium, while it weakens if interest fails to progress and software-sector valuation pressure returns.

Key takeaways on what a potential Waystar sale could mean for healthcare software consolidation

• Waystar Holding Corp. is reported to be exploring strategic options including a possible sale, but no transaction has been announced and a sale may not materialise.
• The company has reportedly engaged Evercore and Barclays to advise on an early-stage process.
• Waystar generated second-quarter revenue of $319.7 million, up 18%, with adjusted EBITDA of $136.7 million and a 43% margin.
• Subscription revenue grew 34%, strengthening the recurring software economics that could appeal to strategic and private equity buyers.
• Waystar had approximately $1.47 billion of outstanding debt at June 30, making financing structure an important element of any take-private transaction.
• Artificial intelligence creates both an opportunity to automate healthcare payment workflows and a competitive risk if parts of traditional software become commoditised.
• Waystar shares closed at $26.67 on September 15 after rising 7.1% during the session and roughly 11.8% from the September 9 close.
• The stock remains materially below its 52-week high of approximately $40.35, potentially creating room for takeover interest despite the recent rally.
• EQT and Canada Pension Plan Investment Board remain significant shareholders, making institutional expectations important to any future sale process.
• The next measurable catalyst is evidence of a formal strategic review, an identified bidder or an actionable acquisition proposal.